Every 8-K that Cryo-Cell International Inc. (CCEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCEL filings page.
Cryo-Cell International, Inc. (CCEL) announced the schedule for its 2026 Annual Meeting of Stockholders. The Board of Directors set October 27, 2026 as the meeting date and September 21, 2026 as the record date for determining which stockholders are entitled to receive notice of and vote at the meeting.
The company also noted that, under its Bylaws, the deadlines for stockholders to submit proposals of business or director nominations for consideration at the 2026 Annual Meeting were both July 27, 2026. These deadlines have already passed.
Cryo-Cell International, Inc. announced that NYSE Regulation has accepted its plan to regain compliance with the continued listing standards of NYSE American. The exchange granted a plan period through September 9, 2027, during which Cryo-Cell’s common stock will continue to trade on NYSE American.
The company was previously notified it was not in compliance with Section 1003(a) of the NYSE American Company Guide due to a stockholders’ deficit as of November 30, 2025 and net losses in two of its three most recent fiscal years. The listing remains subject to ongoing review, and NYSE American may initiate delisting proceedings if Cryo-Cell does not regain compliance or fails to make sufficient progress under the plan.
Cryo-Cell International, Inc. has received a notice from NYSE American that it is not in compliance with continued listing standards under Section 1003(a) of the NYSE American Company Guide. The exchange cited a stockholders’ deficit as of November 30, 2025 and net losses in two of the three most recent fiscal years.
The company’s common stock will continue trading on NYSE American under the symbol CCEL while it prepares and submits a compliance plan, which it intends to file by April 8, 2026. If the plan is not accepted or compliance is not regained within any allowed period, NYSE American may begin delisting proceedings.
Cryo-Cell International (CCEL) announced it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The company stated that future dividends may or may not be paid, with decisions driven by financial performance, capital requirements, and strategic priorities.
This update signals a pause in cash distributions for Q4 FY2025 and places emphasis on deploying resources based on operating needs and strategic plans. The company’s stance leaves flexibility for future payouts if conditions align with its financial and strategic criteria.
Cryo-Cell International (CCEL) amended its credit facilities with Susser Bank. The Fifth Amendment adds wholly owned subsidiary Celle Corp. as a guarantor and updates key terms of the company’s revolving credit facility and term loan.
The revolving credit facility’s commitment was revised to $8,000,000 and its maturity extended to October 18, 2027. The term loan maturity was extended to July 29, 2032. The amendment also sets revised pricing: Base Rate margins of 4.25% for term loans and 3.75% for revolving loans, Monthly SOFR margins of 3.25% for term loans and 2.75% for revolving loans, and a 0.25% commitment fee.
Existing rate constructs and floors remain in place from the 2022 agreement, with the company able to elect Base Rate or Monthly SOFR-based interest. The changes extend maturities while reducing revolver capacity, and add collateral support via a Security Agreement benefiting the lenders.
Cryo-Cell International, Inc. has scheduled its 2025 Annual Meeting of Stockholders for October 21, 2025. The company set September 15, 2025 as the record date, which means only stockholders of record on that date will be entitled to receive notice of and vote at the meeting.
Stockholders who want to present business or nominate directors at the Annual Meeting must deliver the required notice under the Company’s Bylaws no later than the 10th calendar day after public disclosure of the meeting date, which occurred on September 10, 2025.